<DOC>
	<DOCNO>NCT02119312</DOCNO>
	<brief_summary>The purpose study identify screen potential subject preliminary eligibility participate malaria related clinical trial conduct Seattle Malaria Clinical Trials Center ( Seattle MCTC ) one partnering site .</brief_summary>
	<brief_title>Malaria Clinical Trials Center General Screening</brief_title>
	<detailed_description>This continuous study enrol approximately 350 participant per year establish preliminary eligibility participation ongoing future Seattle Malaria Clinical Trials Center ( Seattle MCTC ) clinical research study . Data collect may use support preliminary eligibility current future Seattle MCTC clinical research study . In order maximize efficiency screen process potential participant contact site pre-screened use IRB-approved screening form . Potential participant contact site may ask come in-person screen visit . They give consent form read sign choose participate screening process . If question process research staff available . This visit include in-depth medical history review , travel history , physical exam , blood draw , electrocardiogram test ( ECG ) , urine test . The Seattle Malaria Clinical Trials Center ( Seattle MCTC ) conduct research combat malaria . Malaria disease transmit human bite infect mosquito affect million people worldwide . Malaria cause wide range medical problem , may even result death infection treat . Currently many medication , preventative measure malaria vaccine develop fight malaria need test make available general public . The Seattle MCTC conduct clinical research study purpose need healthy adult volunteer take part upcoming study .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<criteria>Good general health status demonstrate medical history , physical exam , screen laboratory test ; No history certain chronic medical illness ( e.g . diabetes , epilepsy , autoimmune disease , hepatitis , heart disease ) ; HIV , Hepatitis B C negative ; Low risk coronary heart disease ; Ability willingness provide inform consent ; Reliable access MCTC associate site ; If participant biologically female must pregnant must agree consistently use effective form birth control 21 day prior enrollment active clinical study duration study . Prior receipt investigational malaria vaccine ; Chronic use systemic antibiotic immunosuppressive medication antimalarial effect ; Chronic medical condition , physical examination finding , clinically significant abnormal laboratory result , past medical history may clinically significant implication current health status ; History systemic anaphylaxis ; History , know active cardiac disease ; Elevated ( moderate high ) risk coronary heart disease ; Clinically significant ECG finding ; Chronic active neurological disease ; History splenectomy functional asplenia ; History psoriasis porphyria ; History diagnose ocular disease ; Positive history HIV , Hepatitis B and/or C ; Pregnant lactate female female intend become pregnant study period ; Certain psychiatric condition could affect study compliance ; Suspected known current alcohol and/or drug abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Malaria</keyword>
	<keyword>Plasmodium</keyword>
	<keyword>Plasmodium falciparum</keyword>
	<keyword>Clinical Trials</keyword>
	<keyword>Vaccine Study</keyword>
	<keyword>Drug Study</keyword>
	<keyword>Malaria Clinical Trials Center</keyword>
	<keyword>Seattle BioMed</keyword>
	<keyword>Center Infectious Disease Research</keyword>
</DOC>